These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

119 related items for PubMed ID: 7506805

  • 1. Pharmacological profile of KSG-504, a new cholecystokinin-A-receptor antagonist.
    Yamazaki Y, Akahane M, Kobayashi M, Kitazawa M, Kurashina Y, Iizuka K.
    Jpn J Pharmacol; 1993 Oct; 63(2):219-25. PubMed ID: 7506805
    [Abstract] [Full Text] [Related]

  • 2. Cholecystokinin-A specific antagonism of KSG-504 to cholecystokinin receptor binding and pancreatic secretion in mammals.
    Yamazaki Y, Shinagawa K, Takeda H, Kobayashi M, Akahane M, Ajisawa Y.
    Jpn J Pharmacol; 1995 Dec; 69(4):367-73. PubMed ID: 8786640
    [Abstract] [Full Text] [Related]

  • 3. [Effects of KSG-504, a new CCK-A receptor antagonist, on gallbladder and gastrointestinal functions].
    Yamazaki Y, Akahane M, Kobayashi M, Shinagawa K, Sugiura M, Ajisawa Y.
    Nihon Yakurigaku Zasshi; 1996 Jan; 107(1):33-44. PubMed ID: 8720296
    [Abstract] [Full Text] [Related]

  • 4. Effects of KSG-504, a new cholecystokinin-A-receptor antagonist, on pancreatic exocrine and endocrine secretions in rats.
    Yamazaki Y, Akahane M, Kobayashi M, Takeda H, Ajisawa Y.
    Jpn J Pharmacol; 1996 Feb; 70(2):183-90. PubMed ID: 8866756
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A new CCK-A antagonist, KSG-504, administered intraduodenally, inhibits pancreatic secretion in rats.
    Moriyoshi Y, Shiratori K, Takeuchi T, Watanabe S.
    Pancreas; 1994 Mar; 9(2):225-9. PubMed ID: 8190724
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Effects of cholecystokinin (CCK)-JMV-180 on the CCK receptors of rabbit pancreatic acini and gallbladder smooth muscle.
    Taniguchi H, Nagasaki M, Tamaki H.
    Jpn J Pharmacol; 1995 Mar; 67(3):219-24. PubMed ID: 7543168
    [Abstract] [Full Text] [Related]

  • 9. Pharmacological profile of T-0632, a novel potent and selective CCKA receptor antagonist, in vitro.
    Taniguchi H, Yazaki N, Endo T, Nagasaki M.
    Eur J Pharmacol; 1996 May 23; 304(1-3):147-54. PubMed ID: 8813597
    [Abstract] [Full Text] [Related]

  • 10. Pharmacologic profile of TS-941, a new benzodiazepine derivative cholecystokinin-receptor antagonist, in in vitro isolated rat pancreatic acini.
    Tashiro M, Hirohata Y, Kihara Y, Akiyama T, Otsuki M.
    Pancreas; 1999 Mar 23; 18(2):156-64. PubMed ID: 10090413
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Peripheral biological activity of SR 27897: a new potent non-peptide antagonist of CCKA receptors.
    Gully D, Fréhel D, Marcy C, Spinazzé A, Lespy L, Neliat G, Maffrand JP, Le Fur G.
    Eur J Pharmacol; 1993 Feb 23; 232(1):13-9. PubMed ID: 7681406
    [Abstract] [Full Text] [Related]

  • 13. Pharmacological profile of TP-680, a new cholecystokininA receptor antagonist.
    Akiyama T, Tachibana I, Hirohata Y, Shirohara H, Yamamoto M, Otsuki M.
    Br J Pharmacol; 1996 Apr 23; 117(7):1558-64. PubMed ID: 8730754
    [Abstract] [Full Text] [Related]

  • 14. Effects of short-term administration of the CCK receptor antagonist, KSG-504, on regeneration of pancreatic acinar cells in acute pancreatitis in rats.
    Okumura Y, Inoue H, Fujiyama Y, Bamba T.
    J Gastroenterol; 1995 Aug 23; 30(4):493-9. PubMed ID: 7550860
    [Abstract] [Full Text] [Related]

  • 15. [Effect of KSG-504, a new synthetic cholecystokinin receptor antagonist on ethionine-induced acute pancreatitis in rats].
    Okumura Y, Bamba T, Shintani Y, Yoshioka U, Inoue H, Fujiyama Y, Hosoda S.
    Nihon Shokakibyo Gakkai Zasshi; 1993 Dec 23; 90(12):3032-40. PubMed ID: 8283814
    [Abstract] [Full Text] [Related]

  • 16. Pharmacological profile of a new serine derivative cholecystokinin receptor antagonist TP-680 on pancreatic, biliary and gastric function.
    Tachibana I, Kanagawa K, Yamamoto Y, Otsuki M.
    J Pharmacol Exp Ther; 1996 Dec 23; 279(3):1404-12. PubMed ID: 8968365
    [Abstract] [Full Text] [Related]

  • 17. Characterization of a new diphenylpyrazolidinone cholecystokinin antagonist in vitro isolated rat pancreatic acini.
    Akiyama T, Tachibana I, Otsuki M.
    Int J Pancreatol; 1993 Oct 23; 14(2):167-73. PubMed ID: 7506744
    [Abstract] [Full Text] [Related]

  • 18. Effect of a new CCK-A receptor antagonist, dexloxiglumide, on the exocrine pancreas in the rat.
    Varga G, Kisfalvi K, D'Amato M, Scarpignato C.
    J Physiol Paris; 1997 Oct 23; 91(3-5):257-64. PubMed ID: 9403804
    [Abstract] [Full Text] [Related]

  • 19. Pharmacological properties of lorglumide as a member of a new class of cholecystokinin antagonists.
    Makovec F, Bani M, Cereda R, Chisté R, Pacini MA, Revel L, Rovati LA, Rovati LC, Setnikar I.
    Arzneimittelforschung; 1987 Nov 23; 37(11):1265-8. PubMed ID: 3440035
    [Abstract] [Full Text] [Related]

  • 20. A synthetic peptide derivative that is a cholecystokinin receptor antagonist.
    Lignon MF, Galas MC, Rodriguez M, Laur J, Aumelas A, Martinez J.
    J Biol Chem; 1987 May 25; 262(15):7226-31. PubMed ID: 2438274
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.